Scarica l'app Stockscreener
18.15
5.10%
0.88
Dopo l'orario di chiusura:
18.09
-0.06
-0.33%
Precedente Chiudi:
$17.27
Aprire:
$17.07
Volume 24 ore:
2.01M
Relative Volume:
1.02
Capitalizzazione di mercato:
$6.32B
Reddito:
$3.05B
Utile/perdita netta:
$181.32M
Rapporto P/E:
48.66
EPS:
0.373
Flusso di cassa netto:
$186.11M
1 W Prestazione:
+0.06%
1M Prestazione:
+8.75%
6M Prestazione:
+22.47%
1 anno Prestazione:
+93.29%
Intervallo 1D:
$16.87
$18.17
Intervallo di 1 settimana:
$16.77
$18.20
Portata 52W:
$9.20
$19.26
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
18.15 | 6.15B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | UBS | Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media
A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga
Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo
Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock - MarketBeat
Amneal Pharmaceuticals Insiders Sold Shares Worth Over $6.3M - TradingView
Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings - Stock Titan
AMRX (AMRX) files notice to sell 50,000 common shares - Stock Titan
What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders - Sahm
Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan
Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO gains 6.38M shares in Kashiv acquisition - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal - Stock Titan
AMRX (AMRX) plans Rule 144 resale of 146,403 equity compensation shares - Stock Titan
Amneal Pharmaceuticals, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine? - Yahoo Finance
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? - Yahoo Finance
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Shares Fall 4.3% -- GF Value S - GuruFocus
Charles Schwab Corp (AMRX): holder files Form 144 for 2.92M-share sale - Stock Titan
Amneal closes $1.1B Kashiv Biosciences acquisition - NJBIZ
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Amneal Pharma completes acquisition of Kashiv BioSciences - Pharmabiz.com
California State Teachers Retirement System Purchases 56,588 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals Adds $350 Million Incremental Term Loan to Fund Kashiv Acquisition - TradingView
Amneal completes acquisition of Kashiv BioSciences By Investing.com - Investing.com UK
Amneal acquires Kashiv BioSciences, creating global biosimilars leader - Telangana Today
Amneal completes acquisition of Kashiv BioSciences - Investing.com
Amneal Pharmaceuticals Completes Kashiv BioSciences Acquisition - Moomoo
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader - The Manila Times
Amneal's New Global Platform Spans Biosimilar Research to Commercialization - Stock Titan
Oliver Luxxe Assets LLC Has $1.46 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Renaissance Technologies LLC Acquires 260,237 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality - webull.com
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segall Bryant & Hamill LLC Sells 113,969 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Evaluating a Robust 7.43% Potential Upside - DirectorsTalk Interviews
Amneal Reprices $2.08B Term Loan, Cuts Margin 50 Bps; Sees ~$12M Annual Interest Savings - TradingView
UBS raises Amneal Pharmaceuticals price target on biosimilar growth - Investing.com
UBS Adjusts Price Target on Amneal Pharmaceuticals to $25 From $23, Maintains Buy Rating - marketscreener.com
amneal pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
5.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):